The DOI matches its Crossref record; 73 of the 73 references it cites were found in a registry or an index.
Correlates of adjuvanticity: A review on adjuvants in licensed vaccines
Open accessAbstract
After decades of slow progress, the last years have seen a rapid acceleration of the development of adjuvanted vaccines which have lately been approved for human use. These adjuvants consist of different components, e.g. aluminium salts, emulsions such as MF59 and AS03, Toll-like receptor (TLR) agonists (CpG ormonophosphoryl lipid A (MPL) adsorbed on aluminium salts as in AS04) or combination of immunopotentiators (QS-21 and MPL in AS01). Despite their distinctive features, most of these adjuvants share some key characteristics. For example, they induce early activation (although at different levels) of innate immunity which then translates into higher antibody and cellular responses to the vaccine antigens. In addition, most of these adjuvants (e.g. MF59, AS03, AS04) clearly induce a wider breadth of adaptive responses able to confer protection against, for example, heterovariants of the influenza viruses (MF59, AS03) or against human papillomavirus strains not contained in the vaccine (AS04). Finally, the use of some of these adjuvants has contributed to significantly enhance the immune response and the efficacy and effectiveness of vaccines in the elderly who experience a waning of the immune responsiveness to infection and vaccination, as shown for MF59- or AS03-adjuvanted influenza vaccines and AS01-adjuvanted herpes zoster vaccine. These results, together with the track record of acceptable safety profiles of the adjuvanted vaccines, pave the way for the development of novel vaccines at the extremes of age and against infections with a high toll of morbidity and mortality. Here, we review the mechanisms associated with the performance of those adjuvanted vaccines in animal models and in humans through recent advances in systems vaccinology and biomarker discovery. We also provide some perspectives on remaining knowledge gaps but also on opportunities that could accelerate the development of new vaccines.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hornung, V., Bauernfeind, F., Halle, A., Samstad, E. O., Kono, H., Rock, K. L., Fitzgerald, K. A., & Latz, E. (2008) · Nature Immunology · doi:10.1038/ni.1631 · Cited by 3,065
Correlates of protection induced by vaccination
Plotkin, S. A. (2010) · Clinical and Vaccine Immunology · doi:10.1128/cvi.00131-10 · Cited by 1,745
Efficacy of an Adjuvanted Herpes Zoster Subunit Vaccine in Older Adults
Lal, H., Cunningham, A. L., Godeaux, O., Chlibek, R., Diez-Domingo, J., Hwang, S.-J., Levin, M. J., McElhaney, J. E., Poder, A., Puig-Barberà, J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501184 · Cited by 1,454
Efficacy of the Herpes Zoster Subunit Vaccine in Adults 70 Years of Age or Older
Cunningham, A. L., Lal, H., Kovac, M., Chlibek, R., Hwang, S.-J., Díez-Domingo, J., Godeaux, O., Levin, M. J., McElhaney, J. E., Puig-Barberà, J., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603800 · Cited by 1,070
Didierlaurent, A. M., Morel, S., Lockman, L., Giannini, S. L., Bisteau, M., Carlsen, H., Kielland, A., Vosters, O., Vanderheyde, N., Schiavetti, F., et al. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0901474 · Cited by 758
Self-citationVaccine Prevention of Maternal Cytomegalovirus Infection
Pass, R. F., Zhang, C., Evans, A., Simpson, T., Andrews, W., Huang, M.-L., Corey, L., Hill, J., Davis, E., Flanigan, C., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0804749 · Cited by 713
Adjuvant-Enhanced Antibody Responses in the Absence of Toll-Like Receptor Signaling
Gavin, A. L., Hoebe, K., Duong, B., Ota, T., Martin, C., Beutler, B., & Nemazee, D. (2006) · Science · doi:10.1126/science.1135299 · Cited by 581
Kester, K. E., Cummings, J. F., Ofori‐Anyinam, O., Ockenhouse, C. F., Krzych, U., Moris, P., Schwenk, R., Nielsen, R. A., Debebe, Z., Pinelis, E., et al. (2009) · The Journal of Infectious Diseases · doi:10.1086/600120 · Cited by 524
Adjuvant system AS01: helping to overcome the challenges of modern vaccines
Didierlaurent, A. M., Laupèze, B., Di Pasquale, A., Hergli, N., Collignon, C., & Garçon, N. (2017) · Expert Review of Vaccines · doi:10.1080/14760584.2016.1213632 · Cited by 516
Self-citationWheeler, C. M., Castellsagué, X., Garland, S. M., Szarewski, A., Paavonen, J., Naud, P., Salmerón, J., Chow, S.-N., Apter, D., Kitchener, H., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70287-x · Cited by 507
GIANNINI, S., HANON, E., MORIS, P., VANMECHELEN, M., MOREL, S., DESSY, F., FOURNEAU, M., COLAU, B., SUZICH, J., & LOSONKSY, G. (2006) · Vaccine · doi:10.1016/j.vaccine.2006.06.005 · Cited by 496
Molecular and cellular signatures of human vaccine adjuvants
Mosca, F., Tritto, E., Muzzi, A., Monaci, E., Bagnoli, F., Iavarone, C., O'Hagan, D., Rappuoli, R., & De Gregorio, E. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0804699105 · Cited by 492
Self-citationMorel, S., Didierlaurent, A., Bourguignon, P., Delhaye, S., Baras, B., Jacob, V., Planty, C., Elouahabi, A., Harvengt, P., & Carlsen, H. (2011) · Vaccine · doi:10.1016/j.vaccine.2011.01.011 · Cited by 476
Self-citationFranchi, L., & Núñez, G. (2008) · European Journal of Immunology · doi:10.1002/eji.200838549 · Cited by 450
Calabro, S., Tortoli, M., Baudner, B. C., Pacitto, A., Cortese, M., O’Hagan, D. T., De Gregorio, E., Seubert, A., & Wack, A. (2011) · Vaccine · doi:10.1016/j.vaccine.2010.12.090 · Cited by 433
Protection against malaria at 1 year and immune correlates following PfSPZ vaccination
Ishizuka, A. S., Lyke, K. E., DeZure, A., Berry, A. A., Richie, T. L., Mendoza, F. H., Enama, M. E., Gordon, I. J., Chang, L.-J., Sarwar, U. N., et al. (2016) · Nature Medicine · doi:10.1038/nm.4110 · Cited by 367
Khurana, S., Verma, N., Yewdell, J. W., Hilbert, A. K., Castellino, F., Lattanzi, M., Del Giudice, G., Rappuoli, R., & Golding, H. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002336 · Cited by 356
Self-citationGarçon, N., Vaughn, D. W., & Didierlaurent, A. M. (2012) · Expert Review of Vaccines · doi:10.1586/erv.11.192 · Cited by 347
Self-citationOil-in-Water Emulsion Adjuvant with Influenza Vaccine in Young Children
Vesikari, T., Knuf, M., Wutzler, P., Karvonen, A., Kieninger-Baum, D., Schmitt, H.-J., Baehner, F., Borkowski, A., Tsai, T. F., & Clemens, R. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1010331 · Cited by 317
Recent clinical experience with vaccines using MPL- and QS-21-containing Adjuvant Systems
Garçon, N., & Van Mechelen, M. (2011) · Expert Review of Vaccines · doi:10.1586/erv.11.29 · Cited by 314
Systems analysis of protective immune responses to RTS,S malaria vaccination in humans
Kazmin, D., Nakaya, H. I., Lee, E. K., Johnson, M. J., van der Most, R., van den Berg, R. A., Ballou, W. R., Jongert, E., Wille-Reece, U., Ockenhouse, C., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1621489114 · Cited by 293
Franceschi, C., Salvioli, S., Garagnani, P., de Eguileor, M., Monti, D., & Capri, M. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00982 · Cited by 290
Dhimolea, E. (2010) · mAbs · doi:10.4161/mabs.2.1.10328 · Cited by 270
Khurana, S., Chearwae, W., Castellino, F., Manischewitz, J., King, L. R., Honorkiewicz, A., Rock, M. T., Edwards, K. M., Del Giudice, G., Rappuoli, R., et al. (2010) · Science Translational Medicine · doi:10.1126/scitranslmed.3000624 · Cited by 268
Self-citationDidierlaurent, A. M., Collignon, C., Bourguignon, P., Wouters, S., Fierens, K., Fochesato, M., Dendouga, N., Langlet, C., Malissen, B., Lambrecht, B. N., et al. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1400948 · Cited by 266
Self-citationGalli, G., Hancock, K., Hoschler, K., DeVos, J., Praus, M., Bardelli, M., Malzone, C., Castellino, F., Gentile, C., McNally, T., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0903181106 · Cited by 263
Self-citationGalli, G., Medini, D., Borgogni, E., Zedda, L., Bardelli, M., Malzone, C., Nuti, S., Tavarini, S., Sammicheli, C., Hilbert, A. K., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0813390106 · Cited by 261
Self-citationCoccia, M., Collignon, C., Hervé, C., Chalon, A., Welsby, I., Detienne, S., van Helden, M. J., Dutta, S., Genito, C. J., Waters, N. C., et al. (2017) · npj Vaccines · doi:10.1038/s41541-017-0027-3 · Cited by 260
Self-citationNaud, P. S., Roteli-Martins, C. M., De Carvalho, N. S., Teixeira, J. C., de Borba, P. C., Sanchez, N., Zahaf, T., Catteau, G., Geeraerts, B., & Descamps, D. (2014) · Human Vaccines & Immunotherapeutics · doi:10.4161/hv.29532 · Cited by 251
Antigen depot is not required for alum adjuvanticity
Hutchison, S., Benson, R. A., Gibson, V. B., Pollock, A. H., Garside, P., & Brewer, J. M. (2012) · The FASEB Journal · doi:10.1096/fj.11-184556 · Cited by 244
Vandepapelière, P., Horsmans, Y., Moris, P., Van Mechelen, M., Janssens, M., Koutsoukos, M., Van Belle, P., Clement, F., Hanon, E., Wettendorff, M., et al. (2008) · Vaccine · doi:10.1016/j.vaccine.2007.12.038 · Cited by 218
From discovery to licensure, the Adjuvant System story
Garçon, N., & Di Pasquale, A. (2017) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2016.1225635 · Cited by 217
Calabro, S., Tritto, E., Pezzotti, A., Taccone, M., Muzzi, A., Bertholet, S., De Gregorio, E., O’Hagan, D. T., Baudner, B., & Seubert, A. (2013) · Vaccine · doi:10.1016/j.vaccine.2013.05.007 · Cited by 214
Liang, F., Lindgren, G., Sandgren, K. J., Thompson, E. A., Francica, J. R., Seubert, A., De Gregorio, E., Barnett, S., O’Hagan, D. T., Sullivan, N. J., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aal2094 · Cited by 209
Identification of QS-21 as an Inflammasome-activating Molecular Component of Saponin Adjuvants
Marty-Roix, R., Vladimer, G. I., Pouliot, K., Weng, D., Buglione-Corbett, R., West, K., MacMicking, J. D., Chee, J. D., Wang, S., Lu, S., et al. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.683011 · Cited by 204
Cunningham, A. L., Heineman, T. C., Lal, H., Godeaux, O., Chlibek, R., Hwang, S.-J., McElhaney, J. E., Vesikari, T., Andrews, C., Choi, W. S., et al. (2018) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiy095 · Cited by 204
McKee, A. S., & Marrack, P. (2017) · Current Opinion in Immunology · doi:10.1016/j.coi.2017.06.005 · Cited by 197
Wack, A., Baudner, B. C., Hilbert, A. K., Manini, I., Nuti, S., Tavarini, S., Scheffczik, H., Ugozzoli, M., Singh, M., Kazzaz, J., et al. (2008) · Vaccine · doi:10.1016/j.vaccine.2007.11.054 · Cited by 195
Self-citationFourati, S., Cristescu, R., Loboda, A., Talla, A., Filali, A., Railkar, R., Schaeffer, A. K., Favre, D., Gagnon, D., Peretz, Y., et al. (2016) · Nature Communications · doi:10.1038/ncomms10369 · Cited by 183
(2004) · CRC Press eBooks · doi:10.1201/9781439834404 · Cited by 181
Effectiveness of Adjuvanted Influenza Vaccination in Elderly Subjects in Northern Italy
Mannino, S., Villa, M., Apolone, G., Weiss, N. S., Groth, N., Aquino, I., Boldori, L., Caramaschi, F., Gattinoni, A., Malchiodi, G., et al. (2012) · American Journal of Epidemiology · doi:10.1093/aje/kws313 · Cited by 171
AS03- and MF59-Adjuvanted Influenza Vaccines in Children
Wilkins, A. L., Kazmin, D. A., Napolitani, G., Clutterbuck, E., Pulendran, B., Siegrist, C., & Pollard, A. J. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01760 · Cited by 167
The adjuvant MF59 induces ATP release from muscle that potentiates response to vaccination
Vono, M., Taccone, M., Caccin, P., Gallotta, M., Donvito, G., Falzoni, S., Palmieri, E., Pallaoro, M., Rappuoli, R., Di Virgilio, F., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1319784110 · Cited by 164
Self-citationNakaya, H. I., Clutterbuck, E., Kazmin, D., Wang, L., Cortese, M., Bosinger, S. E., Patel, N. B., Zak, D. E., Aderem, A., Dong, T., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1519690113 · Cited by 159
Self-citationSobolev, O., Binda, E., O’Farrell, S., Lorenc, A., Pradines, J., Huang, Y., Duffner, J. L., Schulz, R., Cason, J. W., Zambon, M. C. F. A., et al. (2016) · Nature Immunology · doi:10.1038/ni.3328 · Cited by 156
Burny, W., Callegaro, A., Bechtold, V., Clément, F., Delhaye, S., Fissette, L. A., Janssens, M., Leroux-Roels, G. G., Marchant, A., van den Berg, R. A., et al. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00943 · Cited by 154
Self-citationGavillet, B. M., Eberhardt, C. S., Auderset, F., Castellino, F., Seubert, A., Tregoning, J. S., Lambert, P., Gregorio, E. D., Giudice, G. D., & Siegrist, C. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1402071 · Cited by 150
Dendouga, N., Fochesato, M., Lockman, L., Mossman, S. P., & Giannini, S. L. (2012) · Vaccine · doi:10.1016/j.vaccine.2012.01.088 · Cited by 149
Verdier, F., Burnett, R., Michelet, C., Moretto, P., Fievet-Groyne, F., & Sauzeat, E. (2004) · Vaccine · doi:10.1016/j.vaccine.2004.09.012 · Cited by 135
Detienne, S., Welsby, I., Collignon, C., Wouters, S., Coccia, M., Delhaye, S., Maele, L. V., Thomas, S., Swertvaegher, M., Detavernier, A., et al. (2016) · Scientific Reports · doi:10.1038/srep39475 · Cited by 128
Self-citationInfluenza immunization elicits antibodies specific for an egg-adapted vaccine strain
Raymond, D. D., Stewart, S. M., Lee, J., Ferdman, J., Bajic, G., Do, K. T., Ernandes, M. J., Suphaphiphat, P., Settembre, E. C., Dormitzer, P. R., et al. (2016) · Nature Medicine · doi:10.1038/nm.4223 · Cited by 124
GIUDICE, G., Hilbert, A., Bugarini, R., Minutello, A., POPOVA, O., Toneatto, D., Schöndorf, I., Borkowski, A., Rappuoli, R., & Podda, A. (2006) · Vaccine · doi:10.1016/j.vaccine.2006.01.015 · Cited by 119
Self-citationLysosome-Dependent Activation of Human Dendritic Cells by the Vaccine Adjuvant QS-21
Welsby, I., Detienne, S., N’Kuli, F., Thomas, S., Wouters, S., Bechtold, V., Wit, D. D., Gineste, R., Reinheckel, T., Elouahabi, A., et al. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00663 · Cited by 117
Self-citationLeroux-Roels, G. G., Marchant, A., Lévy, J., Damme, P. V., Schwarz, T. F., Horsmans, Y., Jilg, W., Kremsner, P. G., Haelterman, E., Clément, F., et al. (2016) · Clinical Immunology · doi:10.1016/j.clim.2016.05.007 · Cited by 112
Self-citationTowards an evidence based approach for the development of adjuvanted vaccines
O’Hagan, D. T., Friedland, L. R., Hanon, E., & Didierlaurent, A. M. (2017) · Current Opinion in Immunology · doi:10.1016/j.coi.2017.07.010 · Cited by 107
Self-citationSpensieri, F., Borgogni, E., Zedda, L., Bardelli, M., Buricchi, F., Volpini, G., Fragapane, E., Tavarini, S., Finco, O., Rappuoli, R., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1311998110 · Cited by 100
Self-citationFighting against a protean enemy: immunosenescence, vaccines, and healthy aging
Giudice, G. D., Goronzy, J. J., Grubeck‐Loebenstein, B., Lambert, P., Mrkvan, T., Stoddard, J. J., & Doherty, T. M. (2017) · npj Aging and Mechanisms of Disease · doi:10.1038/s41514-017-0020-0 · Cited by 99
Ansaldi, F., Zancolli, M., Durando, P., Montomoli, E., Sticchi, L., Del Giudice, G., & Icardi, G. (2010) · Vaccine · doi:10.1016/j.vaccine.2010.04.030 · Cited by 96
Francica, J. R., Zak, D. E., Linde, C., Siena, E., Johnson, C. D., Juraska, M., Yates, N. L., Gunn, B. M., Gregorio, E. D., Flynn, B. J., et al. (2017) · Blood Advances · doi:10.1182/bloodadvances.2017011411 · Cited by 91
Inactivated and Adjuvanted Influenza Vaccines
Giudice, G. D., & Rappuoli, R. (2014) · Current topics in microbiology and immunology · doi:10.1007/82_2014_406 · Cited by 86
Self-citationDisparate adjuvant properties among three formulations of “alum”
Cain, D. W., Sanders, S. E., Cunningham, M. M., & Kelsoe, G. H. (2012) · Vaccine · doi:10.1016/j.vaccine.2012.11.044 · Cited by 72
Howard, L. M., Hoek, K. L., Goll, J. B., Samir, P., Galassie, A. C., Allos, T. M., Niu, X., Gordy, L. E., Creech, C. B., Prasad, N., et al. (2017) · PLoS ONE · doi:10.1371/journal.pone.0167488 · Cited by 68
Effectiveness of 2009 pandemic influenza A(H1N1) vaccines: A systematic review and meta-analysis
Lansbury, L., Smith, S. J., BEYER, W. E. P., Karamehić, E., Pašić-Juhas, E., Sikira, H., Mateus, A., Oshitani, H., Zhao, H., Beck, C., et al. (2017) · Vaccine · doi:10.1016/j.vaccine.2017.02.059 · Cited by 63
Galson, J. D., Trück, J., Kelly, D. F., & der Most, R. G. V. (2016) · Scientific Reports · doi:10.1038/srep37229 · Cited by 61
van den Berg, R. A., Coccia, M., Ballou, W. R., Kester, K. E., Ockenhouse, C. F., Vekemans, J., Jongert, E., Didierlaurent, A. M., & der Most, R. G. V. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00557 · Cited by 57
Self-citationKhurana, S., Coyle, E. M., Dimitrova, M., Castellino, F., Nicholson, K. G., Giudice, G. D., & Golding, H. (2014) · PLoS ONE · doi:10.1371/journal.pone.0095496 · Cited by 52
Spensieri, F., Siena, E., Borgogni, E., Zedda, L., Cantisani, R., Chiappini, N., Schiavetti, F., Rosa, D., Castellino, F., Montomoli, E., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0157066 · Cited by 49
Chioato, A., Noseda, E., Felix, S., Stevens, M., Giudice, G. D., Fitoussi, S., & Kleinschmidt, A. (2010) · Clinical and Vaccine Immunology · doi:10.1128/cvi.00175-10 · Cited by 43
Non‐clinical safety and biodistribution of AS03‐adjuvanted inactivated pandemic influenza vaccines
Segal, L. M., Wouters, S., Morelle, D., Gautier, G., Gal, J. L., Martin, T., Kuper, C. F., Destexhe, É., Didierlaurent, A. M., & Garçon, N. (2015) · Journal of Applied Toxicology · doi:10.1002/jat.3130 · Cited by 36
Self-citationSystems Biology of Vaccination in the Elderly
Duraisingham, S., Rouphael, N., Cavanagh, M., Nakaya, H. I., Goronzy, J. J., & Pulendran, B. (2012) · Current topics in microbiology and immunology · doi:10.1007/82_2012_250 · Cited by 35
van Essen, G. A., Beran, J., Devaster, J., Durand, C., Duval, X., Esen, M., Falsey, A. R., Feldman, G., Gervais, P., Innis, B. L., et al. (2014) · Influenza and Other Respiratory Viruses · doi:10.1111/irv.12245 · Cited by 28
Buricchi, F., Bardelli, M., Malzone, C., Capecchi, B., Nicolay, U., Fragapane, E., Castellino, F., Giudice, G. D., Galli, G., & Finco, O. (2012) · European Journal of Immunology · doi:10.1002/eji.201242563 · Cited by 15
Non-recent history of influenza pandemics, vaccines, and adjuvants
Lattanzi, M. (2008) · Birkhäuser Basel eBooks · doi:10.1007/978-3-7643-8371-8_11 · Cited by 7
Cited by
Vaccine adjuvants: mechanisms and platforms
Zhao, T., Cai, Y., Jiang, Y., He, X., Wei, Y., Yu, Y., & Tian, X. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01557-7 · Cited by 1,020
Immunological considerations for COVID-19 vaccine strategies
Jeyanathan, M., Afkhami, S., Smaill, F., Miller, M. S., Lichty, B. D., & Xing, Z. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-020-00434-6 · Cited by 1,015
mRNA-based therapeutics: powerful and versatile tools to combat diseases
Qin, S., Tang, X., Chen, Y., Chen, K., Fan, N., Xiao, W., Zheng, Q., Li, G., Teng, Y., Wu, M., et al. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01007-w · Cited by 771
Alameh, M.-G., Tombácz, I., Bettini, E., Lederer, K., Ndeupen, S., Sittplangkoon, C., Wilmore, J. R., Gaudette, B. T., Soliman, O. Y., Pine, M., et al. (2021) · Immunity · doi:10.1016/j.immuni.2021.11.001 · Cited by 775
Toward Nanotechnology-Enabled Approaches against the COVID-19 Pandemic
Weiss, C., Carriere, M., Fusco, L., Capua, I., Regla-Nava, J. A., Pasquali, M., Scott, J. A., Vitale, F., Unal, M. A., Mattevi, C., et al. (2020) · ACS Nano · doi:10.1021/acsnano.0c03697 · Cited by 601
Metadata
- Authors
- Del Giudice, G., Rappuoli, R., & Didierlaurent, A. M.
- Venue
- Seminars in Immunology
- Publisher
- Elsevier BV
- Published
- 2018-10
- Volume
- 39
- Pages
- 14-21
- ISSN
- 1044-5323 (ISSN-L)
- OpenAlex
- W2803559194
- Cited by
- 610
- References
- 73
- FWCI
- 24.07
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.